Non-Hodgkin Lymphoma

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.

Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

The European Commission has approved liso-cel in relapsed/refractory follicular lymphoma after at least 2 prior lines of systemic therapy.

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Nirav N. Shah, MD, discusses findings from the phase 2 DALY II USA of zamto-cel in relapsed/refractory DLBCL.

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.